Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acasti Pharma Inc. (V:ACST)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ACST within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 22, 2022 18:10 ET
Acasti Pharma Announces Annual Grants of Performance Stock Options
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of...
Read full article
Jun 21, 2022 08:00 ET
Acasti Pharma Reports Fiscal Year 2022 Operational Results
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.36
--
--
Price to Sales - TTM
--
5.14
4.28
Price to Book - most recent quarter
0.37
2.14
1.80
Price to Cash Flow per share - TTM
--
5.94
9.43
Price to Free Cash Flow per share - TTM
--
16.59
18.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 20224,336351
May 31, 20223,985-6,692
May 15, 202210,6778,656
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.

See business summary

 

Twitter

Search (past week) for $ACST.CA ACST.V

  • No tweets found